#United States #Los Angeles #Quest Diagnostics #City of Hope #Haystack MRD

Enhancing Cancer Care Through Innovative Testing

Introduction
Quest Diagnostics has unveiled a collaboration with City of Hope, one of the leading cancer research and treatment organizations in the U.S., to implement their cutting-edge Haystack MRD® test. This partnership will focus on improving patient management strategies in individuals facing breast, colorectal, ovarian, and prostate cancers.

Innovative Technology
Haystack MRD represents a significant advancement in molecular diagnostics as it utilizes circulating-tumor DNA (ctDNA) to detect minimal residual disease (MRD). By assessing the presence of this residual disease, the test has the potential to streamline treatment decisions and enhance the overall management of cancer patients.

This new research initiative is ambitious, with plans to engage around 500 patients from 14 City of Hope locations, including major urban centers such as Los Angeles, Chicago, and Atlanta. The data collected will yield thousands of longitudinal measurements, greatly enhancing the understanding of how such molecular assays can impact cancer treatment.

Clinical Trials and Patient Management
The clinical trials will explore the application of Haystack MRD across various patient management scenarios, including pre-treatment (neoadjuvant), post-treatment (adjuvant), and recurrence surveillance. Initial findings suggest that the test might outperform conventional imaging methods in detecting cancer recurrence and monitoring treatment responses much earlier, providing critical insights for clinicians.

Dr. Cristian Tomasetti, Professor and Director at City of Hope, emphasized the importance of liquid biopsy technologies in oncology, noting that investing in effective ctDNA assays can lead to improved health outcomes. He explained, “Liquid biopsy is a frontier we are excited to explore, and Haystack MRD will play a pivotal role in shaping our understanding of effective cancer treatment.”

Potential Impact on Treatment Decisions
As healthcare evolves, the integration of blood tests such as Haystack MRD is becoming increasingly vital for ensuring timely and accurate treatment interventions. These tests may eliminate the need for chemotherapy in cases where surgery has successfully removed cancerous cells. Dr. Tomasetti further noted that early detection through such technologies can significantly alter how treatment plans are devised and executed.

Dan Edelstein, Vice President at Haystack Oncology, commented on how this partnership with City of Hope aligns with their mission to empower healthcare professionals and patients alike. “We believe that proactive healthcare decisions rooted in solid data will significantly enhance patient care across various cancer types,” he articulated.

About Haystack MRD
The Haystack MRD test's development was a result of over two decades of pioneering work in liquid biopsy technologies from leading institutions like Johns Hopkins School of Medicine. Validation of the test has been conducted in a CLIA-certified environment, and it has garnered recognition, including its Breakthrough Device Designation from the FDA for Stage II colorectal cancer applications. This highlights the test's potential to revolutionize the landscape of cancer diagnostics and patient management.

Conclusion
As City of Hope and Quest Diagnostics move forward with their joint research, they are set to pave new roads in the oncology domain. The incorporation of the Haystack MRD ctDNA test into clinical practice is a testament to the ongoing efforts to enhance cancer care through innovative technologies, ultimately leading towards better health outcomes for patients suffering from various forms of cancer.